Study 7: HOPE-IPF

Principal Investigator

Dr. Parameswaran Nair


Many asthma patients are well controlled using standard asthma treatment such as inhaled steroids and long acting bronchodilators, but some patients are not. Inhaled steroids work well for people with asthma when the type of inflammation in their airways is caused by a type of inflammatory cell called an eosinophil. There is another type of cell that can be in the airways, called a neutrophil. Inhaled steroids do not work well when the inflammation in the airways is due to neutrophils. The investigational drug CXCR2 that is being used in this study helps to reduce the neutrophils in the blood and the airways. We hope that decreasing the neutrophils will help decrease the amount of inflammation in the airways of patients who are not doing well on standard asthma treatment and that this will help to decrease their symptoms.


Approximately 20% of moderate-severe asthmatic patients may have airway neutrophilia. IL-8 and its receptor CXCR2 are involved in this process. This trial evaluates a novel small molecule antagonist of CXCR2 in decreasing asthma exacerbations.

For more information about this study please contact study coordinator Katherine Radford by e-mail at

Accessibility for Ontarians With Disabilities Act (AODA)


The Faculty of Health Sciences is committed to providing a website that is accessible to the widest possible audience. If there is an accessibility issue with this website, please contact us at